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Summary.
Although the majority of lesions reported in children and adolescents are benign, it should be recognized that oral 
malignant tumors do occur in children. The incidence of childhood malignancy is greatest in the 1st year of life, with 
the second peak to be found at 2–3 years of age. Many clinicians do believe that oral cancer is particularly aggressive in 
young patients, and is associated with poorer survival compared to adults. Numerous early reports of oral cancer in young 
adults concluded that the disease was more aggressive, and prognosis was poorer than in older adults.
Purpose of this study is to make a literature review on the diagnostic methods of the tumors of oral cavity in children.
Conclusion. Despite the progress in technology and medicine paraclinical examination methods in determining tu-
mors of the oral cavity in children haven’t been developed and studied enough, thourder studies have to be done in order 
to create diagnostic protocols for the pediatric population.
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Rezumat. Tumorile cavității bucale la copii. Abordare de diagnostic.
Deși majoritatea leziunilor raportate la copii și adolescenți sunt benigne, ar trebui să se recunoască faptul că tumorile 
maligne orale apar la copii. Incidența malignității copilului este cea mai mare în primul an de viață, cel de-al doilea vârf 
fiind întâlnit la vârsta de 2-3 ani. Mulți medici cred că cancerul oral este deosebit de agresiv la pacienții tineri și este 
asociat cu o supraviețuire mai slabă în comparație cu adulții. Numeroase rapoarte timpurii despre cancerul oral la adulții 
tineri au concluzionat că boala era mai agresivă și prognosticul era mai slab decât la adulții în vârstă.
Scopul acestui studiu este de a face o revizuire a literaturii cu privire la metodele de diagnostic ale tumorilor cavității 
bucale la copii.
Concluzie. În ciuda progresului în tehnologia și medicina metodele de examinare paraclinică în determinarea tumo-
rilor cavității bucale la copii nu au fost suficient dezvoltate și studiate, este necesitatea de a efectua studii suplimentare 
pentru a crea protocoale de diagnosticare pentru populația pediatrică.
Cuvinte-cheie: tumoră, cavitate orală, copil, malignitate.
Резюме. Опухоли полости рта у детей. Диагностический подход.
Хотя большинство поражений, о которых сообщалось у детей и подростков, являются доброкачественными, сле-
дует признать, что злокачественные опухоли полости рта действительно встречаются у детей. Заболеваемость злока-
чественными новообразованиями у детей наиболее высока на 1-м году жизни, а второй пик приходится на 2–3 года. 
Многие врачи действительно считают, что рак ротовой полости особенно агрессивен у молодых пациентов и связан с 
более низкой выживаемостью по сравнению со взрослыми. Многочисленные ранние сообщения о раке полости рта у 
молодых людей показали, что болезнь протекает более агрессивно, а прогноз хуже, чем у пожилых людей.
Целью исследования является обзор литературы по методам диагностики опухолей полости рта у детей.
Заключение. Несмотря на прогресс в технологии и медицине, методы параклинического обследования при 
определении опухолей ротовой полости у детей не разработаны и недостаточно изучены, необходимы более глу-
бокие исследования для создания диагностических протоколов для педиатрической популяции.
Ключевые слова: опухоль, полость рта, дети, злокачественность.
Introduction. The oral cavity extends from the ver-
milion border of the lips to the circumvallate papillae of 
the tongue inferiorly and the junction of the hard and soft 
palate superiorly. The oral cavity is divided into sever-
al anatomical subsites: lip, oral tongue, floor of mouth, 
buccal mucosa, upper and lower gum, retromolar trigone 
and hard palate. Despite their proximity, these subsites 
have distinct anatomical characteristics that need to be 
taken into account in planning oncologic therapy [7].
The diagnosis of oral pathologic changes is es-
tablished from the different clinical and radiological 
features, although the final diagnosis is based on his-
topathological examination of the lesion. The initial 
clinical diagnosis must be accurate and should not miss 
any premalignant or malignant pathologic features.
All oral lesions are divided into three groups, in-
cluding non-neoplastic lesions, potentially malignant 
disorders and neoplastic lesions, and are also sub-
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divided into 10 major subcategories: normal tissue, 
inflammatory and infectious lesions, cystic lesions, 
adaptive reactions, potentially malignant disorders, 
autoimmune and metabolic diseases, vascular and 
hemodynamic anomalies, hamartomatous lesions and 
congenital alterations, benign neoplasms and malig-
nant neoplasms. Despite the progress made in recent 
years in the diagnosis and treatment of oral lesions, 
more clinical data are needed to establish their helpful 
clinical pattern [9].
Different lesions affect the oral cavity and jaws. 
They include tumors of odontogenic origin as well as 
non odontogenic tumor and tumor-like lesions. The 
frequency or the ratio of these lesions differs depend-
ing on the population and geographical location. Oth-
er factors, such as age, gender, and localization also 
define lesions [5].
Tumors and tumor-like growths arising from the 
odontogenic tissues constitute a heterogenous group 
of particularly interesting lesions, as they display the 
various inductive interactions that normally occur 
among the embryologic components of the develop-
ing tooth germ. In humans, tumors of odontogenic 
tissues are comparatively rare, comprising about 1% 
of all jaw tumors. In children and adolescents, neo-
plastic lesions are often benign and are of mesenchy-
mal origin [8].
Pediatric cancer is diagnosed in >14,000 U.S. 
children per year from the ages of 0–19 years and 
is the leading cause of disease-related death among 
children aged 1–14 years. Although a few risk factors 
have been conclusively identified, including exposure 
to high dose radiation and certain genetic syndromes, 
the etiology underlying most cases remains unknown. 
Evidence accumulated over several decades suggests 
positive associations between birth defects and pedi-
atric malignancy. Major anomaly examples include 
spina bifida, cleft lip palate, and Down Syndrome. 
Minor anomaly examples include low set ears, epi-
canthal folds, and simian crease. Although certain 
genetic syndromes are known to increase pediatric 
cancer risk (e.g. Down Syndrome and leukemia), oth-
er birth defects (including major and minor), indepen-
dent of known cancer predisposition syndromes, may 
also be associated with an increased risk. Recent evi-
dence suggests that 8.5% of children with cancer har-
bor germline mutations in well-known cancer genes 
that predispose them to the development of early-on-
set malignancy [10].
Oral cancer accounts for about 5% of all malig-
nancies, but occupies an important place in oncologi-
cal pathology due to certain clinical and evolutionary 
features, a wide range of morphological types, very 
diverse treatment methods and different prognosis of 
each location. In the structure of malignant tumors of 
the head and neck, cancer of the oral cavity ranks sec-
ond after laryngeal cancer and is the 8th most com-
mon malignancy. The incidence of oral cancer per 
100,000 population is 10.5 in men and 1.7 – in wom-
en, in men it develops 5-7 times more frequently than 
in women. People aged 60-70 get sick more often, but 
it is also found in young people. Approximately 80% 
of malignant diseases of the oral cavity are squamous 
cell carcinomas. Transitional cell carcinomas and 
lymphoepithelial are a smaller group [1].
Oral cancer has a worldwide incidence of 300,400 
cases and is responsible for 145,400 deaths annual-
ly. The distribution of oral cancer is approximately 
32% in the buccal mucosa, 22% in tongue, 11% in 
lower lip, 11% in palate, 8% in vestibule, 5% in al-
veolus, 5% in floor of the mouth (FOM), and 3% in 
the gingiva. Due to the heterogeneous nature of oral 
cancer, the functional and cosmetic results, and the 
coexistence of frequent medical comorbidities, treat-
ment options should be evaluated through the multi-
disciplinary team and evaluated before reaching the 
final plan. In many countries, surgery remains the 
first option of treatment for oral cancer. The effects 
of oral cancer surgery can have a serious impact on 
a patient’s quality of life and can impair appearance 
and functional characteristics such as speech, masti-
cation, and swallowing [2].
Although the majority of lesions reported in chil-
dren and adolescents are benign and require minimal 
intervention, it should be recognized that oral malig-
nant tumors do occur in children. In general, malig-
nant tumors in children and adolescents comprise less 
than 1% of all diagnoses. Rhabdomyosarcoma is the 
most common soft tissue sarcoma of children, ado-
lescents and young adults representing about 3–4% 
of all cancers affecting children and 35% of cases af-
fecting the head and neck region, like Langerhans cell 
histiocytosis which also has predilection for pediatric 
population [4].
The incidence of childhood malignancy is great-
est in the 1st year of life, with the second peak to 
be found at 2–3 years of age. Although oral cancer 
is much less common among the children compared 
to older adults, according to the recent data approx-
imately 1 in 285 children in the US are diagnosed 
with the disease before the age of 20 years. While ad-
vances in treatment have increased the survival rate 
for many childhood cancers, the disease is still the 
second leading cause of death (following accidents) 
in children ages 5–14 years [2]. Many clinicians do 
believe that oral cancer is particularly aggressive in 
young patients, and is associated with poorer survival 
compared to adults. Numerous early reports of oral 
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cancer in young adults concluded that the disease was 
more aggressive, and prognosis was poorer than in 
older adults [3].
With contemporary multi-modality therapy, the 
5-year survival rate for pediatric malignancies ex-
ceeds 80 %. This success has produced 379,000 
childhood cancer survivors in the USA. As many as 
60 to 90 % of these long-term survivors experience 
adverse health consequences related to cancer or its 
treatment, which may not manifest until years after 
therapy completion. Among treatment-related sequel-
ae, oral and dental complications are common but 
often overlooked sources of morbidity and impaired 
health related quality of life [6].
Diagnosis. Most of the clinicians act on an initial 
clinical diagnosis before embarking on a biopsy to 
establish a tissue diagnosis. This can be beneficial for 
beginning treatment immediately if the initial clini-
cal diagnosis is accurate. There is a data deficiency 
on the assessment of the diagnostic concordance be-
tween the clinical and histopathological diagnosis of 
oral cavity lesions [11].
The clinical TNM stage should be recorded at 
first encounter and modified as evaluation progresses. 
The initial workup consists of diagnosis by biopsy. 
Accessible lesions may be adequately biopsied in the 
clinic using punch forceps, core needle or fine-needle 
aspiration. Some patients will require examination 
under general anesthesia in order to access posteri-
orly located lesions, or to complete a physical exam 
limited by pain and trismus. Radiographic imaging is 
crucial for evaluation of the relation of the tumor to 
adjacent bone and for assessing regional lymph nodes. 
CT scan is the study of choice for evaluation of bone 
and neck nodes, especially early cortical involvement 
and extracapsular nodal spread. MRI provides com-
plementary information about soft tissue extent and 
perineural invasion and is helpful for evaluating the 
extent of medullary bone involvement. Most patients 
with oral cancer are not at risk for distant metastases 
and therefore the role of PET scan in initial assess-
ment is debatable. However, a preoperative PET scan 
may be useful as a baseline if adjuvant treatment is 
anticipated and a PET scan will be used for radiation 
therapy planning (though this is undertaken different-
ly from a „diagnostic” PET scan) [7].
Clear positive associations exist between birth dis-
orders and pediatric cancer with evidence for increased 
risks for specific cancer/birth disorder type combina-
tions. With advances in mutation detection through 
next generation sequencing technologies it may be 
possible to identify genetic causes underlying some of 
these cases, which will provide insight into overlaps 
between genes impacting both development and ma-
lignancy and provide a basis for identification of high 
risk populations among children with congenital ab-
normalities [10]. Next-generation sequencing (NGS) 
technology has expanded in the last decades with sig-
nificant improvements in the reliability, sequencing 
chemistry, pipeline analysis, data interpretation and 
costs. A number of clinical applications are reviewed, 
i.e., mutation detection in inherited cancer syndromes 
based on DNA-sequencing, detection of spliceogenic 
variants based on RNA-sequencing, DNA-sequencing 
to identify risk modifiers and application for pre-im-
plantation genetic diagnosis, cancer somatic mutation 
analysis, pharmacogenetics and liquid biopsy [17].
Fine needle aspiration biopsy
In the oral cavity, the fine needle aspiration biop-
sy method is rarely used. The most common mass-
es biopsied in this manner are odontogenic tumors, 
intraosseous lesions, minor salivary gland tumors, 
sublingual salivary glands and other oral regions. 
However, some reports have described the relevance 
of FNAB for the diagnosis of oral cavity lesions and 
oropharyngeal lesions. The most commonly described 
advantages of the FNAB method are the preoperative 
diagnoses of lesions, clinical follow-up, the ability to 
avoid unnecessary damage to crucial structures of the 
oral cavity, more comfort for the patient and a low 
risk of infection and tissue damage. The most com-
monly reported disadvantages are the fact that there 
is little space to perform the backward and forward 
movement necessary to complete the procedure, and 
the difficulty involved in fixing the lesion. The sen-
sitivity of FNAB in intraoral lesions may vary from 
80% to 100%; specificity varies from 80% to 100% 
and the accuracy varies from 60% to 100%. The false 
positive rate has been reported to vary from 0 to 3% 
and the false negative rate from 0 to 20%. The most 
common diagnostic problem reported during the use 
of FNAB in the oral cavity is an insufficient amount 
of material collected for analysis due to the diffi-
culty of applying the technique in this region [12]. 
Fine-needle aspiration cytology shows high accuracy 
in the diagnosis of pediatric salivary gland tumors, 
with diagnostic sensitivity and specificity similar to 
those reported for adult patients [16].
Computer-assisted analysis of a brush or/and 
scalpel biopsy is a highly sensitive and specific, 
noninvasive test in the evaluation of all oral lesions 
without an etiology. The test is especially beneficial 
when used on lesions that appear clinically benign 
for identifying early stage cancers and dysplasias – 
the lesions for which therapy is most effective. As 
an adjunct to oral cancer examination, its use has the 
potential to reduce the poor mortality rate associated 
with oral malignancies [18].
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18F-FDG PET/CT (Positron Emission Tomogra-
phy/computed tomography)
Compared with PET alone, an open-mouth 
18F-FDG PET/CT scan in patients with oral cavi-
ty carcinomas can improve the tumor localization, 
evaluation of tumor extent, and detection of tumor 
involvement of adjacent structures. Mid-morning 
scheduling of the examination, relaxation of muscles 
before the radiotracer administration, and a wait time 
with the patient upright may reduce the equivocal 
physiologic uptake generally frequent in this area. Fi-
nally, this imaging protocol seems to allow a better 
localization of potentially synchronous tumors [13].
The analysis of saliva as a diagnostic approach 
for systemic diseases was proposed just two decades 
ago, but great interest in the field has emerged recent-
ly because of its revolutionary potential as a liquid bi-
opsy. Saliva is called the mirror of the body, as it is 
considered an ultra-filtrate of the blood and because 
its composition changes under different pathological 
conditions. Multiple molecules isolated from saliva 
can be used as cancer biomarkers for diagnosis, prog-
nosis, drug monitoring and pharmacogenetic studies. 
With all of the above, saliva represents a fluid enriched 
with tumour markers in patients with cancer remote/
distant to the oral cavity. However, further research is 
needed in the different “omics” fields to consider saliva 
a liquid biopsy for a routine clinical usage. Regarding 
challenges in the field, a major limitation in saliva re-
search is identifying specific disease biomarkers with 
high sensitivity and specificity [14].
With advances in molecular biology, viral driv-
en malignancies have gained recognition and tumors 
have become more molecularly defined. According-
ly, diagnostic requirements in head and neck pathol-
ogy have become more refined. Molecular diagnos-
tic modalities, in particular ISH, have become the 
cornerstone of diagnosis in tumors with challenging 
morphology. ISH is an important adjunct to the di-
agnosis of HPV and EBV driven malignancies. Fur-
thermore, FISH is helpful in establishing diagnosis 
in a variety of salivary gland neoplasms including 
pleomorphic adenoma, mucoepidermoid carcinoma, 
secretory carcinoma, hyalinizing clear cell carcino-
ma and adenoid cystic carcinoma. Soft tissue tumors 
including small round blue cell neoplasms and spin-
dle cell neoplasms are difficult due to morphological 
overlap between different entities and FISH is often 
essential in the diagnosis of Ewing sarcoma, rhab-
domyosarcoma, synovial sarcoma, biphenotypic si-
nonasal sarcoma, dermatofibrosarcoma protuberans, 
nodular fasciitis and inflammatory myofibroblastic 
tumor. The use of FISH is also important in sepa-
rating high-grade B-cell lymphomas with MYC and 
BCL2 or BCL6 translocations from DLBCL. FISH 
plays a critical role in the diagnosis of newer entities 
such as HPV-related carcinoma with adenoid cys-
tic like features and adamantinoma-like EFT while 
we still gain experience and familiarity with these 
evolving concepts [15].
Conclusion
The diagnosis of oral pathologic changes is es-
tablished from the different clinical and radiological 
features, although the final diagnosis is based on his-
topathological examination of the lesion. The initial 
clinical diagnosis must be accurate and should not miss 
any premalignant or malignant pathologic features. 
Although the majority of lesions reported in children 
and adolescents are benign, it should be recognized 
that oral malignant tumors do occur in children. Clin-
ical examination of pediatric patients can be found as 
a difficult task to achieve due to age particularities, 
clinical examination under general anesthesia should 
be evaluated in such situations. Despite the progress 
in technology and medicine paraclinical examination 
methods in determining tumors of the oral cavity in 
children haven’t been developed and studied enough, 
thourder studies have to be done in order to create di-
agnostic protocols for the pediatric population.
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Резюме.
В результате изучения динамики заболеваемости рака гортани в Республике Молдова, в период с 1980 по 
2020 гг. было установлено, что ежегодно, злокачественной опухолью гортани, в среднем заболевает около 
120 пациентов. На протяжении 40 лет было выявлено 874 больных, из них больше 80% поступило на лечение в 
3-4 стадии заболевания. В данной статье были изучены результаты хирургического лечения 258 больных с мест-
но-распространенной формой рака гортани. Исходя из особенностей распространения рака гортани на соседние 
органы и ткани, дали нам основание выделить пять основных видов хирургического вмешательства: верхняя, 
нижняя, передняя, задняя и боковая. Оправданность этих операций доказывается продолжительностью жизни 
больного, которая составляет 53,6%.
Ключевые слова: рак гортани, статистика, хирургическое лечение, комбинированное лечение.
